Kymera Therapeutics (NASDAQ: KYMR) is a clinical-stage biopharmaceutical company pioneering a new class of small molecule medicines called targeted protein degraders. Kymera is advancing its proprietary Pegasus™ platform, a drug discovery engine, to design and develop novel therapeutics that selectively degrade disease-causing proteins. Their focus areas include immunology-inflammation and oncology. Kymera aims to address previously undruggable targets and offer new treatment options for patients with serious diseases.
The headquarters serves as the central hub for Kymera's research and development, corporate operations, clinical development, and strategic leadership.
Located within Arsenal Yards, a modern mixed-use development, offering state-of-the-art laboratory and office spaces. The area is known for its vibrant atmosphere and accessibility.
The work culture at Kymera is described as innovative, collaborative, science-driven, and patient-focused, with a strong emphasis on teamwork and scientific excellence to tackle challenging diseases.
Its location in the Boston-Cambridge biotech supercluster provides access to a rich talent pool, leading academic and research institutions, and a network of collaborators and service providers, crucial for a biopharmaceutical company.
Kymera Therapeutics is primarily based in the United States, with its research, development, and corporate operations centered at its Watertown, MA headquarters. While its physical office presence is U.S.-centric, its clinical trials are often conducted globally through partnerships with contract research organizations (CROs) to reach diverse patient populations. Future commercialization efforts for its drug candidates may also involve global partnerships or establishing international operations.
200 Arsenal Yards Blvd, Suite 230
Watertown
MA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Kymera Therapeutics' leadership includes:
Kymera Therapeutics has been backed by several prominent investors over the years, including:
Kymera Therapeutics has maintained relative stability in its core C-suite leadership over the past 12 months, focusing on advancing its clinical pipeline. Any changes generally reflect strategic growth and strengthening of functional capabilities.
Discover the tools Kymera Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Kymera Therapeutics likely utilizes a common corporate email format, often combining elements of an employee's name with the company domain. A frequently observed pattern for companies of this nature is the first initial followed by the last name.
[first_initial][last]@kymeratx.com
Format
jdoe@kymeratx.com
Example
80%
Success rate
GlobeNewswire • 2024-06-03
Kymera Therapeutics presented updated data from its Phase 1 trial of KT-253 in patients with relapsed or refractory high-grade myeloid malignancies and solid tumors. The data showed KT-253's potential with robust p53 induction and evidence of clinical activity, including complete responses....more
GlobeNewswire • 2024-05-09
Kymera reported its Q1 2024 financial results, highlighting progress across its pipeline, including KT-474 (IRAK4 degrader) in hidradenitis suppurativa and atopic dermatitis, and oncology programs KT-333 (STAT3 degrader) and KT-253 (MDM2 degrader). The company emphasized its strong cash position to fund operations....more
GlobeNewswire • 2024-04-08
Kymera presented preclinical data on its STAT6 degrader program at the AACR Annual Meeting 2024, demonstrating potent and selective STAT6 degradation. These findings support the potential of STAT6 degraders as a novel therapeutic approach for a range of allergic and inflammatory diseases, including asthma and atopic dermatitis....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Kymera Therapeutics, are just a search away.